Silver Book Fact

New Medicines in Development for Parkinson’s Disease in 2018

Fact image

America's Biopharmaceutical Companies. Medicines in Development for Neurological Disorders: 2018 Report. Washington, D.C.: PhRMA; 2018. https://www.phrma.org/report/medicines-in-development-for-neurological-disorders-2018-report. Accessed June 11, 2019

Reference

Title
Medicines in Development for Neurological Disorders: 2018 Report
Publication
PhRMA
Publisher
PhRMA
Publication Date
2018
Authors
America's Biopharmaceutical Companies
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • New Medicines in Development for Parkinson’s Disease in 2018
     
  • An Alzheimer’s treatment breakthrough that slowed disease progression and began to show effects in 2015, would reduce Medicaid costs for people with the disease by $62 billion–from the expected $178…  
  • Slowing the progression of Parkinson’s disease by just 10% would save $327 million (in direct and indirect costs) to the U.S. annually.  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2020 out-of-pocket costs to individuals and families dealing with the…  
  • Medicaid Costs, Slowed Progression